SGLT2 inhibitor ‘promising for type 2 diabetes in children, teens’
The adjunctive oral treatment may be an option for young people, for whom approved agents are limited, researchers say
Oral dapagliflozin may be a useful add-on therapy in youth-onset type 2 diabetes but compliance is a problem, a small phase III study suggests.
The AstraZeneca-funded study failed to meet its primary endpoint of reduced HbA1c concentration but in a pre-specified subgroup of patients who adhered to the therapy there was a significant difference for the SGLT2 inhibitor compared with placebo.
The results suggest dapagliflozin is the first oral glucose-lowering agent since metformin shown to be safe and effective in children and young adults with the disease, the researchers say.
Late last year, the European Medicines Agency extended the drug’s indication to include children from the age of 10.
